GGrantIndex
← Search

Flow Cytometry Shared Resource

$1,804P30FY2018CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739Paper 39737640Paper 39726772Paper 39711559Paper 39711135Paper 39684443Paper 39677775Paper 39677720Paper 39677022Paper 39671500Paper 39671496Paper 39630148Paper 39609428Paper 39604567Paper 39603869Paper 39574899Paper 39564580Paper 39554114Paper 39436696Paper 39400608Paper 39384405Paper 39342284Paper 39321266Paper 39311710Paper 39282307Paper 39266537Paper 39264810Paper 39215796Paper 39201277Paper 39191549Paper 39147413Paper 39139560Paper 39136655Paper 39120971Paper 39091762Trial NCT05073848Trial NCT05053737Trial NCT05006040Trial NCT04993859Trial NCT04988490Trial NCT04973007Trial NCT04963283Trial NCT04940468Trial NCT04925193Trial NCT04922112Trial NCT04916990Trial NCT04882111Trial NCT04866758Trial NCT04863092Trial NCT04634110Trial NCT04611022Trial NCT04565457Trial NCT04558138Trial NCT04544592Trial NCT04541407Trial NCT04535102Trial NCT04520867Trial NCT04486573Trial NCT04471363Trial NCT04408092Trial NCT04305366Trial NCT04300478Trial NCT04294693Trial NCT04208243Trial NCT04092803Trial NCT04091867Trial NCT04066218Trial NCT04042935Trial NCT04035408Trial NCT04028167Trial NCT04028063Trial NCT04001101Trial NCT03995082Trial NCT03976193Trial NCT03970226Trial NCT03958565Trial NCT03900793Trial NCT03891654Trial NCT03881098Trial NCT03781154Trial NCT03734653Trial NCT03617679Trial NCT03325634Trial NCT01886859Trial NCT01426334Trial NCT01232829Trial NCT00778167Patent 9434994Patent 8734778Patent 8715649Patent 8343502Patent 8337830Patent 8221763Patent 8153136Patent 8067559Patent 7910315Patent 7595060Patent 7563447Patent 7465454Patent 7083787

Abstract

FLOW CYTOMETRY SHARED RESOURCE (Core-731) ABSTRACT Overview: The Flow Cytometry Shared Resource (FCSR) supports translational and clinical cancer research projects of UCCC members with flow cytometric analysis, high-speed cell sorting, multiplexed fluorescent microsphere assays, and cell counting services. Equipment: FCSR houses three high-speed sorters, four analyzers (3,000 and 8,000 hours/year of cell sorting and analysis capacity, respectively), a new CYTOF 2 mass cytometer, a Luminex Magpix system (1,500 hours/year capacity), and a cell counter. Services: FCSR provides a wide range of assays particularly pertinent to cancer research, including cell cycle, cell proliferation, apoptosis, cell viability, cell signaling, multiplexed cytokine quantitation, stem cell detection, fluorescent protein analysis, and cell phenotyping along with cell sorting. Consultation and Education: FCSR provides consultation to help those members with limited flow cytometry background to design appropriate experiments. In addition, regular educational sessions are held to inform UCCC members and the investigators in their laboratories about the fundamentals of flow cytometry along with information on new techniques and FCSR capabilities. Many investigators also call FCSR on an ad hoc basis for advice on performing experiments. The FCSR also offers assistance and collaboration in the development of new methods. Management: This resource is an institutional core managed by the UCCC and is overseen by the Associate Director for Basic Research. Use of Services: FCSR is among the most highly used of the UCCC shared resources. Since July 2011, 266 investigators have used the services. Sixty-two percent of users (164) were UCCC members, representing all six programs and resulting in 160 peer-reviewed publications. CCSG funding represents 19% of the annual operating budget. The remaining support comes from a NIAMS P30 grant (1%), institutional support (4%) and user fees (75%). Future Directions: FCSR will continue to play a central role in the research conducted by UCCC members by continuing to provide outstanding flow cytometry related services and education and developing cross-disciplinary collaborations with other shared resources. In addition, the FCSR has several future directions that will enhance the SR and UCCC member cancer research including: 1) Raise awareness and promote use of CyTOF2 instrument; 2) Acquire a four- or five-laser analyzer that can detect at least 14 colors and evaluate samples from 96-well plates.

View original record on NIH RePORTER →